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Abstract
Several infrequent genetic polymorphisms in the SERPINA1 gene are known to substantially reduce concentration of alpha1-
antitrypsin (AAT) in the blood. Since low AAT serum levels fail to protect pulmonary tissue from enzymatic degradation,
these polymorphisms also increase the risk for early onset chronic obstructive pulmonary disease (COPD). The role of more
common SERPINA1 single nucleotide polymorphisms (SNPs) in respiratory health remains poorly understood. We present
here an agnostic investigation of genetic determinants of circulating AAT levels in a general population sample by
performing a genome-wide association study (GWAS) in 1392 individuals of the SAPALDIA cohort. Five common SNPs,
defined by showing minor allele frequencies (MAFs) .5%, reached genome-wide significance, all located in the SERPINA
gene cluster at 14q32.13. The top-ranking genotyped SNP rs4905179 was associated with an estimated effect of
b=20.068 g/L per minor allele (P = 1.20*10212). But denser SERPINA1 locus genotyping in 5569 participants with
subsequent stepwise conditional analysis, as well as exon-sequencing in a subsample (N = 410), suggested that AAT serum
level is causally determined at this locus by rare (MAF,1%) and low-frequent (MAF 1–5%) variants only, in particular by the
well-documented protein inhibitor S and Z (PI S, PI Z) variants. Replication of the association of rs4905179 with AAT serum
levels in the Copenhagen City Heart Study (N = 8273) was successful (P,0.0001), as was the replication of its synthetic
nature (the effect disappeared after adjusting for PI S and Z, P = 0.57). Extending the analysis to lung function revealed a
more complex situation. Only in individuals with severely compromised pulmonary health (N= 397), associations of
common SNPs at this locus with lung function were driven by rarer PI S or Z variants. Overall, our meta-analysis of lung
function in ever-smokers does not support a functional role of common SNPs in the SERPINA gene cluster in the general
population.
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Introduction
Alpha1-antitrypsin (AAT) is a serum marker for inflammation
produced in the liver. Its main function is to inhibit neutrophil
elastase and consequently protect pulmonary tissue. The SER-
PINA1 gene encoding the AAT protein is known to be
polymorphic in the general population. The best studied single
nucleotide polymorphisms (SNPs) causing a reduction in AAT
serum levels are the protease inhibitor S (PI S, rs17580) and the
protease inhibitor Z (PI Z, rs28929474) variants [1]. The loss of
function mechanism is especially well investigated for the PI Z
variant. The resulting amino acid change in AAT leads to the
protein’s intracellular polymerization in hepatocytes and therefore
to a reduced level of secreted serum AAT [2]. Homozygosity for
PI Z (PI ZZ genotype) with a frequency of about 0.01% in
Caucasian populations [3] causes blood AAT levels below 30% of
normal. This genotype is clearly associated with elevated chronic
obstructive pulmonary disease (COPD) risk accounting for 1–2%
of all cases [4,5]. There is also strong evidence that accelerated
lung function decline and increased obstructive disease risk can be
caused by compound heterozygosity of PI Z and PI S (PI SZ
genotype). The case is less clear for PI MZ, PI MS or PI SS
genotypes (PI M standing for the normal allele), which cause a less
pronounced reduction in AAT concentration, as previous studies
produced inconsistent evidence [6–9].
Further of note, large-scale genome-wide association studies
(GWAS) on COPD or on cross-sectional or longitudinal lung
function have not identified the SERPINA1 gene to be a major
Genetic Determinants of a1-antitrypsin Serum Level
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genetic determinant [10–12]. But a recent GWAS on emphysema
[13] and a comprehensive evaluation of candidate regions for lung
function [14] reported rs4905179 and rs3748312, two common
SNPs (minor allele frequencies (MAFs) .5%) located in the
SERPINA gene cluster on 14q32.13, among their most strongly
associated results. This locus encompasses SERPINA1 and ten
other genes (SERPINA2 to SERPINA6 and SERPINA9 to
SERPINA13) encoding extracellular ‘clade A’ serpins with very
heterogeneous functions [15]. It is currently not known whether
such association signals observed for this locus reflect a causal role
of common variants or whether they are merely synthetic,
reflecting effects of rarer causal variants [16]. Towards that aim,
but also to detect further chromosomal loci of potential relevance
to circulating levels of AAT, we first performed a GWAS on AAT
serum level using a subset of the population-based Swiss Cohort
Study of Air Pollution and Lung Disease in Adults (SAPALDIA) as
discovery sample, and a second subset of SAPALDIA as well as an
independent cohort, the Copenhagen City Heart Study (hence-
forth referred to as Copenhagen), as replication sample. We also
conducted fine mapping analyses of the SERPINA1 gene in the
SAPALDIA cohort. Finally, we meta-analyzed the lung function
effect of common and low-frequent SERPINA1 SNPs previously
observed to be associated with pulmonary health in ever-smokers,
based on data provided by several population- and patient-based
studies.
Results
The discovery population and the design used to determine
AAT-associated genetic variants are depicted in Figure S1 and
further described in the Materials and Methods section. A
comparison between the characteristics of the genome-wide
analyzed sample (SAPALDIA discovery arm, N=1392) and the
remainder of the SAPALDIA cohort (SAPALDIA replication arm,
N=4245) did not reveal substantial differences in AAT serum
levels or covariate distribution (Table S1), although asthmatics
were overrepresented (39.4%) in the SAPALDIA discovery arm
and absent in the replication arm, which is due to previous study
design [17]. The participants of the independent replication cohort
Copenhagen (N= 8273) were on average five years older and had
twice as many current smokers (Table S1). This was in line with
substantially lower lung function levels (more than 800 mL lower
forced expiratory volume in 1 second, FEV1, compared to both
SAPALDIA subsets) and slightly elevated AAT blood levels
(1.339 g/L vs. 1.257 and 1.255 g/L, respectively). The charac-
teristics of the study populations contributing to the genetic
association analyses with lung function are given in Table S2.
GWAS on AAT Serum Level
The association of more than 2.1 million genome-wide SNPs
with AAT serum levels is shown in Figure 1. The ten most
strongly associated SNPs were all located in the SERPINA gene
cluster, half of them reached genome-wide significance
(P,5*1028, Table 1). The top 100 ranking SNPs are provided
in Table S3. A regional association plot for the SERPINA gene
cluster is shown in Figure 2. Both the top-ranking imputed SNP,
rs2736887, and the top-ranking genotyped SNP, rs4905179, were
located in close proximity to the SERPINA6 gene and approx-
imately 33 kb and 50 kb downstream of SERPINA1 (effect
estimates b=20.071 and 20.068 g/L per minor allele;
P = 2.48*10213 and 1.20*10212, respectively). Linkage disequi-
librium (LD) between these two variants based on HapMap2
CEU (Utah residents with Northern and Western European
ancestry) derived haplotype data [18] was strong (r2 = 0.88,
D9=1), but Figure 2 suggests that the LD, expressed in r2 values,
between the top-ranking SNP and the other SNPs in the region is
generally modest. The genomic inflation factor lambda was low
(l=1.02), suggesting minimal population stratification. The
quantile-quantile plot (Q-Q plot) showed good adherence to null
expectation and substantial positive deviation between observed
and expected p-values for the top-ranking SNPs (Figure S2). In a
sensitivity analysis adjusting for additional covariates, including
high sensitivity C-reactive protein (hs-CRP), body mass index
(BMI), passive smoking and alcohol intake, the genome-wide
association results did not show an increase in the strength of the
top-ranking loci, nor did they point to additional loci (data not
shown). Even though this GWAS was enriched with asthma
patients, GWAS stratification according to asthma status did not
show heterogeneity for the top-ranking signals between partici-
pants with and without asthma (data not shown).
Association of 1000 Genomes Imputed Data for the
SERPINA Gene Cluster with AAT Serum Level
In order to further refine association signals in this region, we
imputed additional SNPs on chromosome 14 using haplotype
data from the 1000 Genomes Project (1000G) [19]. The 1000G
imputation yielded a three times higher number of imputed
variants with reasonable quality scores (imputation-r2.0.5)
compared to HapMap-derived imputed variants. A region
defined by 1 Mb up- and downstream of the SERPINA1 gene
revealed 24 additional variants that were associated below a
local significance level of P,3*1025, adjusting for approximately
1800 SNPs covering a region of 2 Mb (Table S4). Among them,
four low-frequent variants and one rare variant showed p-values
reaching genome-wide significance level, and interestingly, none
of them was in high LD (r2.0.8) with any other regional variant
tested. The most strongly associated signal came from the PI Z
variant, which is well known to be associated with reduced
AAT serum levels (b=20.620 g/L per minor allele,
P = 4.61*10243, MAF=0.84%). The other well established
Author Summary
Low levels of alpha1-antitrypsin (AAT) in the blood are a
well-established risk factor for accelerated loss in lung
function and chronic obstructive pulmonary disease. While
a few infrequent genetic polymorphisms are known to
influence the serum levels of this enzyme, the role of
common genetic variants has not been examined so far.
The present genome-wide scan for associated variants in
approximately 1400 Swiss inhabitants revealed a chromo-
somal locus containing the functionally established vari-
ants of AAT deficiency and variants previously associated
with lung function and emphysema. We used dense
genotyping of this genetic region in more than 5500
individuals and subsequent conditional analyses to unravel
which of these associated variants contribute indepen-
dently to the phenotype’s variability. All associations of
common variants could be attributed to the rarer
functionally established variants, a result which was then
replicated in an independent population-based Danish
cohort. Hence, this locus represents a textbook example of
how a large part of a trait’s heritability can be hidden in
infrequent genetic polymorphisms. The attempt to transfer
these results to lung function furthermore suggests that
effects of common variants in this genetic region in ever-
smokers may also be explained by rarer variants, but only
in individuals with hampered pulmonary health.
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causal polymorphism, the PI S variant, was less prominently
ranked (b=20.110 g/L per minor allele, P = 1.95*1026,
MAF= 5.70%) and exhibited an insufficient imputation quality
(imputation-r2 = 0.45).
GWAS on AAT Serum Level, Conditional on PI S and PI Z
Variants
Accuracy of the imputed PI S and PI Z results was confirmed by
direct genotyping of the samples [20]. The discovery arm revealed
33 PI Z carriers, 111 PI S carriers and two compound
heterozygous carriers of PI S and PI Z (MAF=1.26% for PI Z
and 4.06% for PI S, respectively). No homozygous PI S or PI Z
genotypes were detected.
To test the influence of these variants on the initially reported
GWAS results (Figure 1), we performed a conditional GWAS by
additionally adjusting the regression models for the presence of PI
S and PI Z alleles. We observed a drastic change in the
association of the SERPINA gene cluster SNPs with AAT serum
Figure 1. Manhattan plot of genome-wide -log(10) p-values for association with AAT serum level. SNPs reaching genome-wide
significance are shown in green. They all belong to the SERPINA gene cluster.
doi:10.1371/journal.pgen.1003585.g001
Table 1. The ten most strongly associated SNPs in the unconditional GWAS on AAT serum level in SAPALDIA (N = 1392).
SNP Chromosome Position Gene Location Determination MAF Imp-r2
Allele
Effect P
rs2736887 14 93882733 intergenic imputed 0.185 0.950 0.071 2.48E-13
rs926144 14 93883155 intergenic imputed 0.186 0.950 0.071 2.72E-13
rs7151526 14 93933389 SERPINA1 59UTR imputed 0.065 0.769 0.116 6.78E-13
rs4905179 14 93865245 SERPINA6 59UTR genotyped 0.180 1.000 0.068 1.20E-12
rs11621961 14 93839229 SERPINA6 39UTR genotyped 0.355 0.945 0.052 1.37E-11
rs17751837 14 93937997 SERPINA1 59UTR genotyped 0.097 0.995 0.063 8.56E-08
rs1028580 14 93919635 SERPINA1 intron imputed 0.154 0.979 0.051 4.87E-07
rs8010121 14 93920367 SERPINA1 intron genotyped 0.155 0.999 0.049 6.64E-07
rs3748312 14 93924017 SERPINA1 intron imputed 0.148 0.846 0.053 9.84E-07
rs17752593 14 94007781 SERPINA9 intron genotyped 0.129 0.997 0.053 1.59E-06
Abbreviations: AAT, alpha1-antitrypsin; GWAS, genome-wide association study; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Imp-r2 is an indicator for imputation quality. SNPs with MAF,0.05 or imp-r2,0.5 were excluded.
Chromosomal position is based on reference panel, NCBI build 36.3. Allele effects are shown in absolute numbers.
doi:10.1371/journal.pgen.1003585.t001
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level (Figure 3 and Table 2). The strong signal on chromosome
14 observed in the original GWAS disappeared completely and
the top-ranking imputed and genotyped SNPs (rs2736887 and
rs4905179) were no longer significant (P = 0.44 and 0.31,
respectively). In fact, no SNP was found near the SERPINA gene
cluster among the 100 most strongly associated common variants
(Table S5). In addition, the 1000G imputed data, comprising
sequences 1 Mb up- and downstream of the SERPINA1 gene, did
not show evidence of other independent AAT-associated SNPs.
An alternative approach that excluded all PI S and PI Z carriers
from the GWAS sample (N= 146), instead of adjusting for them,
confirmed the results. Both analyses revealed an intergenic region
on chromosome 3 with borderline genome-wide significance (top-
ranking SNP rs2566347, b=20.043 g/L per minor allele,
P = 7.88*1028, in the adjusted GWAS). The top SNPs in this
region were located in proximity to MFSD1 and RARRES1, which
are two genes with sparsely annotated function. The 1000G
imputation of this region did not reveal further variants. In
addition, we were unable to replicate this association signal in the
SAPALDIA replication arm (N= 4245, b=20.004 g/L per
minor allele, P = 0.46).
Replication in the Copenhagen City Heart Study
The effect of rs4905179, the top genotyped SNP in our GWAS,
on AAT serum levels was tested for replication in Copenhagen
(Table 3). The minor allele was associated with b=20.097 g/L
(P,0.0001, N=8332). As observed in the GWAS, adjustment for
PI S and Z polymorphisms resulted in a complete loss of this signal
(b=0.003 g/L, P= 0.57, N= 8273).
Impact of Common and Low-Frequent SERPINA1 Genetic
Variants on AAT Serum Level
In a first fine mapping step, 16 SERPINA1 SNPs (see Materials
and Methods section for a description of the SNP selection) were
successfully genotyped in 5569 SAPALDIA subjects (discovery and
replication arm combined). The genotype results in the discovery
arm allowed us to compare allele frequencies with imputed results
derived from the 1000G data. Table S6 shows that the agreement
was very high. Stepwise conditional regression analyses were then
applied to evaluate the independent effects of each of these SNPs
on AAT serum levels (Table 4). The PI Z variant was most
strongly associated with circulating levels of AAT. The PI S
variant remained strongly associated after conditioning on PI Z.
Two variants located in the 59 non-coding gene region (rs2896268
and rs1956707) were marginally associated with the phenotype in
two further steps after conditioning on PI S and PI Z. The total
variance of AAT explained by statistical models increased from
8.8% (model with only non-genetic factors) to 32.6% (adding PI S
and PI Z alleles), and to 32.8% adding rs2896268 and rs1956707.
Based on genotype data from the SAPALDIA cohort, the
SERPINA1 gene contains three haplotype blocks using D9-based
block definition (Figure 4). The AAT deficiency variants PI S and
PI Z are located in block 1, while rs2896268 and rs1956707 are
located in block 3, roughly 8 kb upstream of exon 1.
Impact of Rare SERPINA1 Genetic Variants on AAT Serum
Level
In a second fine mapping step, exon sequencing was performed
in 410 subjects with low AAT levels that were independent of the
Figure 2. Regional plot for the SERPINA gene cluster (93.8–94.2 Mb on chromosome 14q32.13, reference panel: NCBI build 36.3).
Presented are -log(10) p-values and LD (r2) with top-ranking SNP rs2736887 (purple diamond) for all SNPs in this region. The blue line shows
recombination rate.
doi:10.1371/journal.pgen.1003585.g002
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presence of PI S or PI Z alleles [21]. 16 additional SERPINA1
variants (two deletions and 14 SNPs) were detected, of which all
but one had already been described [21–29] (Table S7). Three
of the SNPs were synonymous, and five had no accession
numbers in public databases (as of April 1st, 2013). Most of the
non-synonymous SNPs have already been described as poten-
tially lowering AAT serum level, and computational tools only
classified one of them as no damaging to the protein’s tertiary
structure. In order to estimate the phenotypic influence of these
rare variants, we compared mean AAT blood levels, adjusted for
sex, age, study center, current smoking, as well as for the
presence of PI S and Z alleles, between samples without rare
variants (N= 346) and those with a single rare variant (N= 63)
or more than one (N= 1). The subjects with rare variants had a
lower adjusted mean AAT level (0.904 g/L, 95% CI 0.884 to
0.924 g/L) compared to those without rare variants (0.992 g/L,
95% CI 0.984 to 1.000 g/L, P,0.001). Although this difference
is small, the range covers the recently proposed upper limit of
intermediate AAT deficiency (0.92 g/L), a value with some
clinical relevance [20]. AAT levels of carriers of synonymous
mutations or non-synonymous mutations without predicted
damaging consequences to protein structure (N= 20) were not
different from those carrying no rare variants (0.985 vs. 0.990 g/
L, P= 0.77). Assuming that unsequenced samples were negative
for mutations with predicted deleterious functional effects, the
total variance of explained AAT further increased from 32.8%
to 35.4% (based on a statistical model adding all rare
mutations with predicted damaging consequences to the protein
structure).
Common and Low-Frequent SERPINA1 SNPs Previously
Associated with Lung Function
Results from a previous GWAS on emphysema [13] and a
large-scale evaluation of candidate loci on lung function [14]
pointed to a role of common variants in the SERPINA gene cluster.
The SNPs rs4905179 (associated with emphysema in smokers [13])
and rs3748312 (associated with cross-sectional lung function
among ever smokers [14]) were strongly associated with AAT in
our study (Tables 1 and 4), but both signals disappeared upon
adjustment for the low-frequent variants PI S and Z. In order to
clarify whether the association of the two common SNPs with
pulmonary health could also be explained by effects of the rarer
SNPs, we conducted a meta-analysis for cross-sectional lung
function in ever-smokers across 17 studies with a total sample size
of N= 24,446 (Table S2). We included nine studies which had
contributed to the original finding on lung function [14] and had
available genotypes or 1000G imputed genotype data on PI S and
Z. The meta-analysis in cohorts of general population study design
showed that rs4905179 was not associated with lung function in
ever-smokers (P = 0.90 in the fixed-effect meta-analysis,
N= 20,153, Figure 5). Yet smaller studies recruited within
population isolates showed a trend for the rare allele to be
associated with low lung function (random-effect P= 0.02,
N= 1623, Figure 5), and in contrast to the association with AAT
serum levels, adjusting for PI S and Z alleles did not modify the
association of rs4905179 with lung function (Figure 6). For the
second common SNP, rs3748312, we could nominally replicate
the statistically significant allele effect on FEV1 in the general
population of ever-smokers (P = 0.02, N=15,450), and the
Figure 3. Manhattan plot of genome-wide -log(10) p-values for association with AAT serum level, conditional on PI S and PI Z
alleles.
doi:10.1371/journal.pgen.1003585.g003
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stronger effect that was published [14] seems to be driven by
population isolates (Figure 7). Again, as for rs4905179, the
associations were not dependent on S and Z alleles (Figure 8).
Meta-analyses of the associations of PI S and Z alleles with lung
function revealed no consistent associations between these
functional AAT level determining variants and reduced FEV1
(Figures S3 and S4). Remarkably, the significant associations of
rs4905179 and rs3748312 with lung function assessed in two
additional studies with patients featuring compromised pulmonary
health and undergoing lung resection, showed evidence for
synthetic associations of the common SNPs with lung function
that are consistent with our results for circulating AAT (Table 5).
The minor alleles were associated with lower lung function and the
association completely disappeared when conditioned on the
presence of PI S and Z alleles.
Discussion
We present here the first GWAS on circulating AAT blood
levels. Our results confirm that genetic variation in the SERPINA1
gene is a strong determinant of serum AAT levels. Fine mapping
of SERPINA1 and subsequent stepwise regression analyses further
revealed that the associations with common variants in the
SERPINA locus could be attributed to rarer variants previously
identified to be causally linked with AAT deficiency.
There is an ongoing debate about whether rare variants are
responsible for the missing heritability observed in GWAS on
many complex outcomes [30]. We show here an example in which
the polymorphisms PI S and PI Z seem to account for basically all
observable effects of common variants in the SERPINA gene
cluster on AAT serum level. The top-ranking genotyped SNP in
our GWAS, rs4905179, was in low r2-based LD with PI S
(r2 = 0.18) and PI Z (r2 = 0.06), reflecting in part the unequal allele
frequencies of these SNPs. However, PI S and PI Z showed very
high LD in terms of D9 with the GWAS top signals (e.g. D9=0.95
and 0.96, respectively, with rs4905179) and generally with many
common variants in this locus (Figure 4), suggesting little genetic
recombination. This proof-of-principle approach, revealing that
signals of common variants in fact merely reflect rarer variants, has
recently also been shown for some of the loci regulating low-
density lipoprotein (LDL) cholesterol [31,32]. Yet for other loci
linked to LDL cholesterol, as well as for loci influencing other
traits, both common and low-frequent variants contributed
independently of the original GWAS signal to the phenotypic
trait [31,33,34].
Using regional 1000G imputation within the top-ranking loci
can allow the identification of additional association signals of
stronger size to support the initial GWAS top result, as observed
here for the SERPINA cluster, but not for the locus near MFSD1,
an association which was not confirmed in the SAPALDIA
replication arm. The resequencing strategy of the GWAS-
identified locus in a sample with low AAT concentrations yielded
in the identification of rare variants being strongly associated with
reduced AAT blood levels. Such an accumulation of rare variants
in the extreme range of the respective phenotype has also been
reported by others [35,36]. As for the relative contribution of
Table 2. The ten most strongly associated SNPs in the GWAS on AAT serum level, conditional on PI S and PI Z alleles in SAPALDIA
(N= 1392).
SNP Chromosome Position Gene Location Determination MAF Imp-r2
Allele
Effect P
rs2566347 3 159974071 intergenic imputed 0.192 0.998 0.043 7.88E-08
rs1560417 3 159972476 intergenic imputed 0.200 0.998 0.042 1.11E-07
rs1560418 3 159972335 intergenic genotyped 0.200 1.000 0.042 1.11E-07
rs1430414 3 159987697 MFSD1 59UTR imputed 0.137 0.984 0.045 9.26E-07
rs6761989 3 159983253 intergenic imputed 0.137 0.993 0.044 1.14E-06
rs17643917 3 159968433 intergenic imputed 0.137 1.000 0.044 1.23E-06
rs17643860 3 159967954 intergenic imputed 0.137 1.000 0.044 1.24E-06
rs17700475 3 159967627 intergenic genotyped 0.137 1.000 0.044 1.25E-06
rs3863076 3 159969394 intergenic genotyped 0.145 1.000 0.042 1.69E-06
rs2206593 1 184909052 PTGS2 39UTR genotyped 0.065 0.956 0.060 4.60E-06
Abbreviations: AAT, alpha1-antitrypsin; GWAS, genome-wide association study; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Imp-r2 is an indicator for imputation quality. SNPs with MAF,0.05 or imp-r2,0.5 were excluded.
Chromosomal position is based on reference panel, NCBI build 36.3. Allele effects are shown in absolute numbers.
doi:10.1371/journal.pgen.1003585.t002
Table 3. Minor allele effects of PI S, PI Z and rs4905179 on AAT serum levels in the Copenhagen City Heart Study.
SNP N MAF (genotyped) Allele Effect (g/L) 95% Confidence Intervals P
rs17580 (PI S) 8338 0.029 20.188 20.211 to 20.165 ,0.0001
rs28929474 (PI Z) 8338 0.027 20.492 20.514 to 20.470 ,0.0001
rs4905179 8332 0.186 20.097 20.107 to 20.087 ,0.0001
rs4905179, adjusted for PI S and Z 8273 0.186 0.003 20.007 to 0.013 0.57
Abbreviations: MAF, minor allele frequency; SNP, single nucleotide polymorphism.
doi:10.1371/journal.pgen.1003585.t003
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genetic variants on the phenotype, we confirmed that effect sizes of
PI S and Z on AAT serum levels were comparably strong,
explaining alone a high proportion of the total variability (24.2%).
We estimated that rare variants explained at least another 2% in
our population-based sample, but since we did not sequence the
entire SAPALDIA sample for rare variants, we cannot reliably
quantify this contribution. In terms of blood markers, similar
examples exist in which one genetic variant could explain well
above 5% of the phenotype’s variability (e.g. lipoprotein(a) [37],
bilirubin [38] or adiponectin [39]), but for many other markers
like serum lipid levels, only variants with small effects have been
detected so far [40].
Association patterns between SERPINA1 variants and circulat-
ing AAT did not translate to according associations with lung
function level in a straightforward manner. Lung function is a
complex phenotype associated with numerous genetic variants
[11,12]. Studies on the associations of SERPINA1 polymorphisms
with lung function and COPD have produced mixed results. It is
well accepted that severe AAT deficiency caused by PI null
mutations or by the presence of two PI Z alleles puts a subgroup of
carriers at higher risk of emphysema and COPD, especially when
smoking [5]. Studies on COPD found suggestive evidence for an
association with heterozygous status for the PI Z allele [6,8], but
we observed no associations in our meta-analysis between PI Z
and lung function level in ever-smokers. In the SAPALDIA
general population sample, we had previously reported that an
effect of the PI Z allele on lung function decline is restricted to
persistent smokers and primarily observed for forced expiratory
flow 25–75% [9]. Other variation in or close to the SERPINA1
gene has been proposed to play a role for pulmonary health. First,
a haplotype pattern of five common SNPs was reported to be more
frequent in COPD cases than in controls in a study with limited
statistical power [41]. The only SNP which was also separately
associated with COPD in that analysis was not associated with
reduced serum levels in our study (rs8004738, Table 4). Second,
the minor allele of rs4905179, which was the top signal in the
current AAT GWAS, was positively associated with emphysema
assessed by chest tomography in three independent cohorts
consisting of smoking COPD patients without severe AAT
deficiency (PI ZZ) [13]. Finally, the minor allele of the intronic
SNP rs3748312 was positively associated with lung function in
ever-smokers from different population-based studies of the
SpiroMeta Consortium [14]. The association of these two SNPs
with lung function in ever-smokers was heterogeneous across
studies in our meta-analysis. Dependency on PI S and Z was
limited to studies in patients with lung resection (Groningen,
UBC), consistent with the notion that SERPINA1 may only confer
risk in selected population subgroups.
There are several possible explanations for the poor translation
of genetic association patterns with serum AAT to lung function
and for the heterogeneity of associations between SERPINA1
variants and lung function. First, lung function is influenced by
mechanisms in addition to protease-antiprotease disequilibrium.
Second, the contribution of the SERPINA1 gene variants as a
Table 4. Common and low-frequent SERPINA1 SNPs and their association with AAT serum level, univariate and conditional on
significantly associated SNPs (N = 5569a), in SAPALDIA.
SNP Location Position Selectionb MAF Univariate
c Conditionald
Allele Effect P
Allele
Effect P
rs2896268 59UTR 93935461 C 0.495 0.006 0.10 0.013 4.1E-05
rs1956707 59UTR 93933946 C 0.038 0.016 0.10 0.029 5.0E-04
rs8004738 exon 1 93926667 D 0.490 0.005 0.15 0.001 0.81
rs1570142 intron 1 93926015 A,B,C 0.488 0.005 0.19 0.001 0.88
rs3748312 intron 1 93924017 A,B 0.153 0.035 2.4E-12 0.002 0.70
rs3748316 intron 1 93923617 A,C 0.181 0.011 0.02 0.002 0.63
rs3748317 intron 1 93923432 A 0.158 0.020 5.5E-05 0.004 0.36
rs1980617 intron 1 93922287 A 0.389 0.030 5.0E-16 0.003 0.31
rs1980618 intron 1 93922176 A,C 0.383 0.030 1.3E-16 0.005 0.15
rs2753935 intron 1 93920690 A 0.435 0.012 9.7E-04 0.004 0.24
rs2144831 intron 1 93919723 A,C 0.240 0.021 9.8E-07 0.002 0.71
rs709932 exon 2 93918954 A,C 0.169 0.021 1.2E-05 0.003 0.50
rs6647 exon 3 93917168 A,C 0.200 0.026 7.2E-09 0.003 0.51
rs17580 (PI S) exon 3 93917015 D 0.041 0.210 1.9E-127 0.218 1.9E-163
rs28929474 (PI Z) exon 5 93914700 D 0.013 0.483 1.3E-240 0.482 5.2E-269
rs1303 exon 5 93914596 A,C 0.247 0.015 4.7E-04 0.001 0.89
Abbreviations: AAT, alpha1-antitrypsin; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Chromosomal position is based on reference panel, NCBI build 36.3.
aIncludes subjects for whom all the 16 SNPs have been successfully genotyped.
bSNP selection was based on extreme trait sequence data (A), tagging SNPs according to HapMap (B), TAMAL software (C) and publication about functionality (D); see
Materials and Methods for a more detailed description.
cUnivariate analyses were adjusted for non-genetic factors only (sex, age, recruiting area and current smoking status). Allele effects are shown in absolute numbers and
P,0.005 was considered statistically significant.
dIn a forward selection approach of stepwise regression, the four SNPs in bold contributed statistically significantly to the variability in AAT serum levels and were
included in the final statistical model. Allele effects and p-values refer to this final model.
doi:10.1371/journal.pgen.1003585.t004
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determinant of lung function likely depends on both the
evolutionary pressure in isolated populations and the prevalence
of effect modifiers in the respective study populations. These
include smoking and smoking intensity, and likely other markers of
inflammation. AAT itself plays a dual role in its relationship with
lung function. While chronic AAT deficiency is etiologically
associated with adverse pulmonary health, individuals with lung
function impairment in fact exhibit higher AAT levels for a given
genetic background due to AAT’s role as an acute-phase
inflammation marker [42,43]. Third, tissue-specific regulation of
the SERPINA1 locus may play an important role. Serum AAT
levels are driven by SERPINA1 expression, protein formation and
secretion in hepatocytes, so that regulatory SNPs associated with
serum AAT likely reflect processes in the liver. One way to infer
causality of potentially regulatory SNPs is by testing if they are
simultaneously associated with health outcome and gene expres-
sion in the relevant tissue [44]. We therefore conducted a look-up
in an expression quantitative loci (eQTL) database of lung tissue
[45], but could not find any common variant which was
significantly associated in cis with the transcripts deriving from
the SERPINA1 locus. In a recent study on networks of blood
metabolites, the SNPs rs11628917 and rs1884549 were the most
strongly associated blood and liver eQTLs with respect to
SERPINA1 expression [46]. They both lie in the 39 untranslated
region of SERPINA1, but were not associated with blood AAT in
our GWAS (P= 0.80 and P=0.21, respectively). Moreover, we
could not detect epistasis between those variants and the
deleterious coding variants PI S and Z in terms of AAT serum
levels. The absence of such an interaction does not point to
regulatory function of the common SNPs [47] and argues in favor
of tissue-specific heterogeneity. Forth, the role of SERPINA1 in
selected subgroups of persons exhibiting accelerated lung function
decline or COPD needs to be considered from a perspective
beyond genetic variation, as a recent study investigating epigenetic
mechanisms of disease revealed methylation status of the
SERPINA1 gene to be most strongly associated with cross-sectional
lung function and COPD [48].
The strength of this study is that it combines the report of a
GWAS on AAT serum levels with meta-analyses of the
associations of some of the GWAS top variants with lung
function. The effects of the underlying functional variants are
thoroughly investigated resulting in the hitherto largest meta-
Figure 4. LD plot among common and low-frequent SNPs in the SERPINA1 gene within the SAPALDIA study. Shading represent r2
values, whereas numbers represent D9 values (no number equals D9=1). Red framed SNPs are independently associated with AAT serum levels after
forward selection stepwise regression modeling. Rs17580 is the PI S variant and rs28929474 is the PI Z variant.
doi:10.1371/journal.pgen.1003585.g004
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analysis of PI S and Z on FEV1 in ever-smokers. Ascertainment
and study design of the many participating studies were
sufficiently diverse to informatively address heterogeneity in
association of common and rarer variants in the SERPINA gene
cluster with lung function. The strength of the discovery sample
is the population-based study design and the detailed charac-
terization of the participants. Sex, age and smoking are
important modifiers of AAT blood levels in the general
population [43] and were included in all regression models.
More refined smoking variables covering smoking intensity were
not included as this information is less complete than smoking
status in SAPALDIA and would lower the sample size. By
excluding samples with elevated hs-CRP values we avoided the
masking of AAT deficiencies due to a chronic or acute
inflammation. On the methodological side, conditional analysis
is a well-established tool for identifying independent signals
within a certain locus [38,49,50]. Furthermore, 1000G imputa-
tion was able to point to the causal variant demonstrating its
reliability to correctly assign alleles close to the 1% MAF
threshold.
The limitations of this investigation include firstly the small
sample size of the GWAS discovery arm, resulting in a high
susceptibility to false negative findings. We calculated 63% power
to detect SNPs with an allele effect of 0.1 g/L AAT serum level
( = 2.4% of the phenotypic variance) to a genome-wide significance
level of 5*1028. However, if we define the clinically important
threshold of AAT as the upper limit of intermediate AAT
deficiency, which has been recently suggested as 0.92 g/L [20], we
have more than 99.9% power to detect such a large-impact
variant. Nevertheless, genes that contribute to AAT serum levels
with smaller effects than SERPINA1 were likely to be missed. This
could be a reason why neither SNPs in interleukin 6 (IL-6) nor in
hepatocyte nuclear factor 1a (HNF-1a)/HNF-4, both important
regulators of AAT expression [51], were associated with circulat-
ing AAT concentrations. Furthermore, by sequencing only the
coding region of SERPINA1, rare variants in introns and outside
the gene could not be determined. Another potential limitation of
our GWAS on AAT serum level is the overrepresentation of
asthmatics in the discovery sample. Asthma patients usually show
higher levels of inflammatory markers in their lungs. However, we
did not find heterogeneity in the effects of the most strongly
associated SNPs when comparing asthmatics with non-asthmatics.
Moreover, AAT mean values between the discovery and the
replication arm were not significantly different, as participants
with elevated hs-CRP had been excluded.
In conclusion, our study confirms the SERPINA1 locus as the
major genetic determinant of AAT blood levels. Methodolog-
ically, it represents a powerful example how low-frequent
variants, separated by several kilobases from the top-ranking
GWAS signals, can create purely synthetic associations which
do not add to the variance of the respective outcome. In terms
of lung function, our data do not support a functional role of
Figure 5. Forest plot of meta-analyzed results for the effect per minor allele of rs4905179 on FEV1 in ever-smokers, adjusted for
sex, age, height and population stratification factors. Studies based on population isolates with a high degree of cryptic relatedness are
presented separately. Effect estimates of meta-analyses are shown with green diamonds. I2 is a measure of the heterogeneity between studies.
Random effect meta-analyses are included if I2.0.5. Study weights (blue squares) correspond to fixed effect meta-analyses.
doi:10.1371/journal.pgen.1003585.g005
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any common SNP in the SERPINA cluster in the general
population.
Materials and Methods
Ethics Statement
SAPALDIA was approved by the Swiss Academy of Medical
Sciences, the national ethics committee for clinical research
(UREK, Project Approval Number 123/00) and the Cantonal
Ethics Committees for each of the eight examination areas
(Ethics commissions of the cantons Aargau, Basel, Geneva,
Grisons, Ticino, Valais, Vaud and Zurich). Participants were
required to give written consent before any part of the health
examination was conducted either globally (for all health
examinations) or separately for each investigation. For ethics
statements of the additional studies contributing to this work, see
Table S8.
Study Population
SAPALDIA. In 1991, a random sample of 9651 adults,
aged 18–60 years, from eight areas in Switzerland responded
to a questionnaire about respiratory health, occupational and
lifestyle exposures. 99.0% of them also underwent spirometry
testing [52]. Eleven years later, 8047 persons were reassessed
and 6058 subjects provided blood samples and consented to
DNA analysis [53]. In the present study, we used a subgroup of
the second survey (N = 1640) that underwent genotyping in the
context of the GWAS on asthma by the GABRIEL consortium
[17]. This sample included all asthmatics (positive answer to
the question ‘‘Have you ever had asthma?’’ at either survey) as
well as a random sample of non-asthmatic controls. 248
participants were removed due to several reasons, including
elevated levels of the inflammatory marker hs-CRP (.10 mg/
L, N = 54), leading to a discovery arm of 1392 individuals
(Figure S1). The discovery arm contained 548 (39.4%) self-
declared asthmatics, whereas there were no self-declared
asthmatics in the replication arm. Both the discovery and the
replication sample were submitted to a first step of fine
mapping of SERPINA1 resulting in 5569 individuals from
whom all the selected SNPs could be successfully determined.
In a second step, a subsample with abnormally low AAT
measurements additionally underwent SERPINA1 exon se-
quencing.
Additional Studies. The populations are briefly described in
Table S8.
Phenotype Measurements
AAT serum levels in SAPALDIA were determined by latex-
enhanced immunoturbidimetric assays (Roche Diagnostics, on a
Roche Cobas Integra analyzer) with interassay coefficients of
Figure 6. Forest plot of meta-analyzed results for the effect per minor allele of rs4905179 on FEV1 in ever-smokers, adjusted for
sex, age, height, population stratification factors and the presence of PI S and Z alleles. Studies based on population isolates with a high
degree of cryptic relatedness are presented separately. Effect estimates of meta-analyses are shown with green diamonds. I2 is a measure of the
heterogeneity between studies. Random effect meta-analyses are included if I2.0.5. Study weights (blue squares) correspond to fixed effect meta-
analyses.
doi:10.1371/journal.pgen.1003585.g006
Genetic Determinants of a1-antitrypsin Serum Level
PLOS Genetics | www.plosgenetics.org 11 August 2013 | Volume 9 | Issue 8 | e1003585
variation below 5% and lower detection rate of 0.21 g/L. Serum
concentrations in Copenhagen were measured by immunoturbidi-
metric assays (Thermo Scientific, on a Thermo Scientific Konelab
analyzer) with coefficients of variation below 5% and lower
detection rate of 0.10 g/L.
Lung function was measured in all participating studies by
spirometry without bronchodilation ([52] and Table S8). In the
patient-based studies, in which a lung resection was carried out
(Groningen, UBC), lung function measurements were carried out
prior to the intervention.
Genotyping
SAPALDIA. Genomic DNA was extracted from blood sam-
ples using the Puregene DNA Isolation Kit (Gentra Systems).
Genotyping of the GWA-bound subset was performed on the
Illumina Human 610quad array. Asthmatic and non-asthmatic
samples were tested in random blinded order to avoid systematic
array-related artifacts. 567,589 autosomal SNPs were satisfactorily
genotyped (mean call rate: 99.7%). 69,892 were excluded from
analysis due to violation of Hardy Weinberg Equilibrium (HWE,
P,1024), low call rate (,97%) or MAF,5%.
Genotyping of GWAS finding rs2566347 on chromosome 3 in
the SAPALDIA replication arm was carried out using the
MassARRAY iPLEX Gold (Sequenom).
The SNPs selected in the first fine mapping step were genotyped
by polymerase chain reaction (PCR) with fluorescently labeled
Taq-Man probes (Vic or Fam labels) on a Light Cycler 480 (Roche
Diagnostics). All SNPs were in HWE (P.0.01) [20].
Additional Studies. PI S and Z genotypes were determined
by PCR in Copenhagen and LHS as previously described [54,55].
The SNP rs4905179 was genotyped in the course of GWAS
projects in B58C, BHS, Copenhagen, Korcula, KORA S3,
KORA F4, LBC36, LHS, NSPHS, ORCADES, Split, UBC,
and Vis.
Imputation
SAPALDIA. We have carried out genome-wide imputation
from 60 CEU HapMap2 (release 22, NCBI build 36) reference
panels [18] using MACH 1.0.16 [56] resulting in 2,588,592
autosomal HapMap-based SNPs. 2,168,668 SNPs fulfilled the
quality criteria, which are as mentioned above for genotyped SNPs
and additionally consisted of an imputation-r2.0.5.
Further imputation was carried out in the most promising loci
using 566 EUR reference haplotypes from the August 2010 release
of 1000G on the MACH (pre-phasing) and Minimac-omp
programs. SNPs with an imputation-r2.0.5 and MAF.0.1%
passed the quality check.
Additional Studies. Rs4905197 was imputed based on
1000G reference panels in Groningen, NFBC66, and SHIP
(imputation-r2$0.99). Rs3748312, rs17580 (PI S) and rs28929474
(PI Z) were 1000G imputed in B58C, BHS, Groningen, Korcula,
KORA S3, KORA F4, LBC36, NFBC66, NSPHS, ORCADES,
Figure 7. Forest plot of meta-analyzed results for the effect per minor allele of rs3748312 on FEV1 in ever-smokers, adjusted for
sex, age, height and population stratification factors. Studies based on population isolates with a high degree of cryptic relatedness are
presented separately. Effect estimates of meta-analyses are shown with green diamonds. I2 is a measure of the heterogeneity between studies.
Random effect meta-analyses are included if I2.0.5. Study weights (blue squares) correspond to fixed effect meta-analyses.
doi:10.1371/journal.pgen.1003585.g007
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Split, SHIP, UBC, and Vis (imputation-r2 0.86–0.98, 0.69–0.83,
and 0.82–0.98, respectively).
SERPINA1 SNP Selection for Fine Mapping in SAPALDIA
In an attempt to find AAT modifying SERPINA1 gene variants
acting independently of each other, a multiple strategy to
optimally cover the gene was applied. Sequencing of the whole
SERPINA1 gene in 25 unrelated samples from the Italian registry
of AAT deficiency which demonstrated extreme phenotypes was
used to identify common SNPs not present in HapMap. Extreme
phenotypes consisted of 11 samples with AAT.1.60 g/L and hs-
CRP ,8 mg/L, 3 samples with PI ZZ or PI SZ genotype and
AAT,0.20 g/L, 2 samples with PI MZ genotype and
AAT,0.60 g/L, as well as 9 non-carriers of PI S or PI Z alleles
Figure 8. Forest plot of meta-analyzed results for the effect per minor allele of rs3748312 on FEV1 in ever-smokers, adjusted for
sex, age, height, population stratification factors and the presence of PI S and Z alleles. Studies based on population isolates with a high
degree of cryptic relatedness are presented separately. Effect estimates of meta-analyses are shown with green diamonds. I2 is a measure of the
heterogeneity between studies. Random effect meta-analyses are included if I2.0.5. Study weights (blue squares) correspond to fixed effect meta-
analyses.
doi:10.1371/journal.pgen.1003585.g008
Table 5. Minor allele effects on FEV1 of low-frequent and common SNPs in the SERPINA gene cluster in ever-smokers undergoing
lung resection.
SNP MAF Imp-r
2
Allele
Effect (L) P MAF Imp-r2
Allele
Effect (L) P
Groningen (N=133) University of British Columbia, UBC (N=264)
rs17580 (PI S) 0.055 0.72 0.42 0.10 0.079 0.76 20.15 0.29
rs28929474 (PI Z) 0.123 0.98 20.68 ,0.001 0.032 0.98 20.81 ,0.0001
rs4905179 0.299 1.00 20.22 0.04 0.249 naa 20.23 0.002
rs4905179, adjusted for PI S and Z 20.07 0.65 20.08 0.36
rs3748312 0.233 0.95 20.34 0.008 0.148 0.94 20.16 0.07
rs3748312, adjusted for PI S and Z 0.16 0.37 0.09 0.35
Abbreviations: FEV1, forced expiratory volume in one second; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Imp-r2 is an indicator for imputation quality. The analyses were adjusted for age, sex and height.
aRs4905179 was genotyped in UBC.
doi:10.1371/journal.pgen.1003585.t005
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with blood levels .0.65 and ,1.10 g/L. In these 25 samples, a
total of 129 mutations were identified in the SERPINA1 gene. After
removing SNPs which were monomorphic in our data, SNPs
deviating from HWE or lying in high LD with an adjacent marker
(D9.0.8 and r2.0.4 according to JLIN [57]), we finally obtained a
list of 22 common SNPs (Table 4, selection A). In a second
strategy, HapMap CEU data was used to select tagging SNPs
(Haploview 3.32) [58], resulting in 8 polymorphisms (selection B).
Third, TAMAL [59] was used to identify promising SNPs in the
region of the SERPINA1 gene (selection C). Pairwise LD and the
feasibility of designing a corresponding TaqMan assay reduced the
number of SNPs to 13. Two established (PI S and Z) and one
suggestive (rs8004738 [60]) functional SNPs were added (selection
D), resulting in 16 SNPs used in the conditional analysis. Three of
them were already part of the SNP array genotyped for the
GWAS. The 5 SNPs in coding regions (exons 2–5) were all non-
synonymous.
Exon Sequencing in SAPALDIA
We sequenced 410 individuals with abnormally low AAT levels
with the Sanger chain-termination method. Different thresholds
according to the deficiency genotypes and hs-CRP values were
applied to define an abnormally low AAT concentration (PI MM:
1.13 g/L if hs-CRP .8 mg/L and 1.00 g/L if hs-CRP #8 mg/L;
PI MS: 0.85 g/L; PI MZ: 0.65 g/L) [21]. The cut-off of 1.13 g/L
was earlier reported to be the best to differentiate AAT-deficient
patients from healthy individuals [61]. Since exon 1 is non-coding,
the sequencing procedure was only applied to exons 2 to 5.
Statistical Analysis
AAT serum levels were only marginally skewed to the right,
and a log-transformation of these data was omitted since it led to
a stronger deviation from normality. Student’s t-test was used to
compare adjusted mean AAT levels between different subgroups
of the sequenced samples. The genome-wide association of 2.17
million quality-controlled SNPs with serum AAT levels was
assessed using fixed effects linear regression with ProbABEL [62].
An additive genetic model was applied and the association was
adjusted for sex, age, study center, dichotomous current smoking
status, as well as population stratification factors. To account for
population stratification, we relied on previously inferred
ancestry-informative principal components using EIGENSTRAT
2.0 software [63] and HapMap data, as well as additional
reference European samples [64]. Cryptic relatedness was
detected based on identity-by-state (IBS) analysis. Influence of
additional suggestive determinants of AAT, such as hs-CRP,
BMI, alcohol intake and passive smoking was assessed in a
sensitivity analysis. We also performed genome-wide analysis
conditioned on the functionally established PI S and PI Z
variants. Bonferroni correction for multiple testing was applied,
resulting in P,5*1028 to designate genome-wide significance,
taking account of one million independent tests for common
variants across the genome. For the SNPs imputed by using
1000G reference samples, we considered a three times lower p-
value as adequate as roughly three times more SNPs on
chromosome 14 passed an imputation-r2 threshold of 0.5
(219,471 1000G-derived variants vs. 82,296 HapMap2-derived
variants). Applying this to a 2 Mb chromosomal stretch (with
approximately 600 HapMap2-derived SNPs) resulted in a
significance threshold of roughly 3*1025.
For the replicated SNP in the SAPALDIA replication arm, as
well as for the lung function analysis, a two-sided p-value of 0.05
was considered significant. We investigated heterogeneity between
asthmatics and non-asthmatics in the discovery arm by testing for
a difference between the two effects, using a chi-square test with
one degree of freedom.
Replication analysis for AAT in Copenhagen, as well as
association analyses of the 16 genotyped SERPINA1 SNPs in both
the SAPALDIA discovery and replication arm, was carried out
applying the same statistical model as in the GWAS apart from the
adjustment for population stratification factors. Stepwise condi-
tional analyses were conducted by testing each SNP for AAT
association after including at each step the most significantly
associated SNP in the model. As some of these SNPs turned out to
be in unexpectedly high LD, we applied a threshold level for
statistical significance of P= 0.005, accounting for approximately
ten independent tests [65].
To be as close as possible to the calculations carried out in the
original publication [14], multivariate linear regression models for
lung function analyses were used adjusted for sex, age, height and
population stratification factors (if available).
All the SAPALDIA regression analyses were performed with
STATA 12.1 IC.
Further Software
Manhattan, Q-Q and forest plots were created with the help of
R 2.15.1 (www.r-project.org). Regional association plots were
drawn using LocusZoom [66]. Pairwise LD was calculated for
HapMap2 and 1000G CEU data using SNAP [67]. The LD plot
was produced with HaploView 4.2 [58]. The effect of non-
synonymous SNPs on protein structure was predicted by SIFT
[68]. Finally, Quanto 1.2.4 (hydra.usc.edu/gxe/) was used for
power calculations for the GWAS.
Supporting Information
Figure S1 SAPALDIA study design for the determination of
AAT associated genetic variants.a consisting of subjects with
abnormally low AAT levels independent of PI S or Z alleles (see
Materials and Methods).
(TIF)
Figure S2 Q-Q plot of genome-wide -log(10) p-values for
association with AAT serum level.
(TIF)
Figure S3 Forest plot of meta-analyzed results for the effect per
minor allele of rs17580 (PI S) on FEV1 in ever-smokers, adjusted
for sex, age, height and population stratification factors. Studies
based on population isolates with a high degree of cryptic
relatedness are presented separately. Effect estimates of meta-
analyses are shown with green diamonds. I2 is a measure of the
heterogeneity between studies. Random effect meta-analyses are
included if I2.0.5. Study weights (blue squares) correspond to the
fixed effect meta-analyses.
(TIF)
Figure S4 Forest plot of meta-analyzed results for the effect per
minor allele of rs28929474 (PI Z) on FEV1 in ever-smokers,
adjusted for sex, age, height and population stratification factors.
Studies based on population isolates with a high degree of cryptic
relatedness are presented separately. Effect estimates of meta-
analyses are shown with green diamonds. I2 is a measure of the
heterogeneity between studies. Random effect meta-analyses are
included if I2.0.5. Study weights (blue squares) correspond to the
fixed effect meta-analyses.
(TIF)
Table S1 Characteristics of SAPALDIA follow-up participants
belonging to the discovery (N= 1392) and replication arm
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(N= 4245), and of participants of the Copenhagen City Heart
Study (N= 8273).
(DOC)
Table S2 Characteristics of study populations contributing to
the SNP association analyses with FEV1.
(XLS)
Table S3 The top 100 ranking SNPs associated with AAT
serum level in SAPALDIA (N=1392).
(DOC)
Table S4 SERPINA regional variants based on 1000 Genomes
imputation reaching statistical significance for the association with
AAT serum level in SAPALDIA (N=1392).
(DOC)
Table S5 The top 100 ranking SNPs associated with AAT
serum level, conditional on PI S and Z alleles in SAPALDIA
(N=1392).
(DOC)
Table S6 Accuracy of 1000 Genomes based imputation in the
SERPINA1 region in SAPALDIA (N=1392).
(DOC)
Table S7 Further variants in the SERPINA1 coding region,
present in a SAPALDIA subsample with abnormally low AAT
serum levels (N=410).
(DOC)
Table S8 Descriptions and acknowledgments of individual
studies contributing to the SNP association analyses with FEV1.
(XLS)
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